Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5444_Библиотеки_им_академика_М_И_Перельмана
.pdf
10 Nanodelivery of Polyphenols as Nutraceuticals in Anticancer Interventions
218
124 Park, J.W. and Han, J.W. (2019). Targeting epigenetics for cancer therapy. Archives of Pharmacal
Research 42: 159–170.
125
Nikolaou, S. and Machesky, L.M. (2020). The stressful tumour environment drives plasticity of
cell migration programmes, contributing to metastasis. The Journal of Pathology 250 (5): 612–623.
126
Hamidi, H. and Ivaska, J. (2018). Every step of the way: integrins in cancer progression and
metastasis. Nature Reviews Cancer 18 (9): 533–548.
127
Haibe, Y., Kreidieh, M., El Hajj, H. et al. (2020). Resistance mechanisms to anti-angiogenic
therapies in cancer. Frontiers in Oncology 10: 221.
128
McCubrey, J.A., Steelman, L.S., Chappell, W.H. et al. (2007). Roles of the Raf/MEK/ERK pathway
in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta
(BBA) - Molecular Cell Research 1773 (8): 1263–1284.
129
Starok, M., Preira, P., Vayssade, M. et al. (2015). EGFR inhibition by curcumin in cancer cells: a
dual mode of action. Biomacromolecules 16 (5): 1634–1642.
130
Zhou, H. and Huang, S. (2011). Role of mTOR signaling in tumor cell motility, invasion and
metastasis. Current Protein and Peptide Science 12 (1): 30–42.
131
Wang, M., Yu, T., Zhu, C. et al. (2014). Resveratrol triggers protective autophagy through the
ceramide/Akt/mTOR pathway in melanoma B16 cells. Nutrition and Cancer 66 (3): 435–440.
132
Bhattacharya, S., Darjatmoko, S.R., and Polans, A.S. (2011). Resveratrol modulates the malignant
properties of cutaneous melanoma via changes in the activation and attenuation of the anti-
apoptotic proto-oncogenic protein Akt/PKB. Melanoma Research 21 (3): 180.
133
Leo, M.S. and Sivamani, R.K. (2014). Phytochemical modulation of the Akt/mTOR pathway and
its potential use in cutaneous disease. Archives of Dermatological Research 306: 861–871.
134
Dhar, S., Kumar, A., Rimando, A.M. et al. (2015). Resveratrol and pterostilbene epigenetically
restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer.
Oncotarget 6 (29): 27214.
135
Li, J., Gong, X., Jiang, R. et al. (2018). Fisetin inhibited growth and metastasis of triple-negative
breast cancer by reversing epithelial-to-mesenchymal transition via PTEN/Akt/GSK3β signal
pathway. Frontiers in Pharmacology 9: 772.
136
Yao, X., Jiang, W., Yu, D. et al. (2019). Luteolin inhibits proliferation and induces apoptosis of
human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the
PI3K/AKT pathway. Food and Function 10 (2): 703–712.
137
Achen, M.G. and Stacker, S.A. (2008). Molecular control of lymphatic metastasis. Annals of the
New York Academy of Sciences 1131 (1): 225–234.
138 Luo, H., Rankin, G.O., Juliano, N. et al. (2012). Kaempferol inhibits VEGF expression and in vitro
angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway. Food Chemistry 130 (2): 321–328.
139 Paramanantham, A., Kim, M.J., Jung, E.J. et al. (2020). Pretreatment of anthocyanin from the
fruit of vitiscoignetiaepulliat acts as a potent inhibitor of TNF-α effect by inhibiting NF-κB-
regulated genes in human breast cancer cells. Molecules 25 (10): 2396.
140
Boye, K. and Mælandsmo, G.M. (2010). S100A4 and metastasis: a small actor playing many roles.
The American Journal of Pathology 176 (2): 528–535.
141 Saleem, M., Adhami, V.M., Ahmad, N. et al. (2005). Prognostic significance of metastasis-
associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens
in an autochthonous mouse model. Clinical Cancer Research 11 (1): 147–153.
142 Coussens, L.M. and Werb, Z. (2002). Inflammation and Cancer. Nature 420 (6917): 860–867.
https://doi.org/10.1038/nature01322. PMID: 12490959; PMCID: PMC2803035.
https://t.me/medicina_free
References 219
143 Hiam-Galvez, K.J., Allen, B.M., and Spitzer, M.H. (2021). Systemic immunity in cancer. Nature
Reviews Cancer 21 (6): 345–359. https://doi.org/10.1038/s41568-021-00347-z. Epub 2021 Apr 9.
PMID: 33837297; PMCID: PMC8034277.
144
Mileo, A.M., Nisticò, P., and Miccadei, S. (2019). Polyphenols: immunomodulatory and
therapeutic implication in colorectal cancer. Frontiers in Immunology 10: 729. https://doi.
org/10.3389/fimmu.2019.00729. PMID: 31031748; PMCID: PMC6470258.
145
Shakoor, H., Feehan, J., Apostolopoulos, V. et al. (2021). Immunomodulatory effects of dietary
polyphenols. Nutrients 13 (3): 728. https://doi.org/10.3390/nu13030728.
146
Karasawa, K., Uzuhashi, Y., Hirota, M. et al. (2011). A matured fruit extract of date palm tree (Phoenix
dactylifera L.) stimulates the cellular immune system in mice. Journal of Agricultural and Food
Chemistry 59 (20): 11287–11293. https://doi.org/10.1021/jf2029225. Epub 2011 Oct 3. PMID: 21936496.
147
Malfitano, A.M., Pisanti, S., Napolitano, F. et al. (2020). Tumor-associated macrophage status in
cancer treatment. Cancers (Basel) 12 (7): 1987. https://doi.org/10.3390/cancers12071987. PMID:
32708142; PMCID: PMC7409350.
148
Nishida-Aoki, N. and Gujral, T.S. (2022). Fisetin inhibits lipopolysaccharide-induced macrophage
activation and dendritic cell maturation. Cancer Research 82 (3): 433–446. 10.1158/0008-5472.
CAN-21-1428. Epub 2021 Dec 13. PMID: 34903600; PMCID: PMC8847322.
149
Liu, S.H., Lin, C.H., Hung, S.K. et al. (2010). Fisetin inhibits lipopolysaccharide-induced
macrophage activation and dendritic cell maturation. Journal of Agricultural and Food Chemistry
58 (20): 10831–10839. https://doi.org/10.1021/jf1017093. Epub 2010 Oct 5. PMID: 20923145.
150
Tekin, İ.Ö. and Marotta, F. (2018). Polyphenols and immune system. Polyphenols: Prevention and
Treatment of Human Disease (Second Edition) 263–276. https://doi.org/10.1016/
b978-0-12-813008-7.00022-9.
151
Wang, Y., Ni, H., Li, H. et al. (2018). Nuclear factor kappa B regulated monocyte chemoattractant
protein-1/chemokine CC motif receptor-2 expressing in spinal cord contributes to the
maintenance of cancer-induced bone pain in rats. Molecular Pain 14: 1744806918788681. https://
doi.org/10.1177/1744806918788681. Epub 2018 Jun 29. PMID: 29956585; PMCID: PMC6055241.
152 Yoshimura, T., Howard, O.M., Ito, T. et al. (2013). Monocyte chemoattractant protein-1/CCL2
produced by stromal cells promotes lung metastasis of 4T1 murine breast cancer cells. PLoS One
8 (3): e58791. https://doi.org/10.1371/journal.pone.0058791. Epub 2013 Mar 18. PMID: 23527025;
PMCID: PMC3601078.
153 Yoshimura, T., Galligan, C., Takahashi, M. et al. (2014). Non-myeloid cells are major contributors
to innate immune responses via production of monocyte chemoattractant protein-1/CCL2.
Frontiers in Immunology 4: 482. https://doi.org/10.3389/fimmu.2013.00482. PMID: 24432017;
PMCID: PMC3882876.
154 Andujar, I., Recio, M.C., Giner, R.M. et al. (2012). Cocoa polyphenols and their potential benefits
for human health. Oxidative Medicine and Cellular Longevity 2012: Article ID 906252. 23.
155 Neurath, M.F. (2019). IL-23 in inflammatory bowel diseases and colon cancer. Cytokine and
Growth Factor Reviews 45: 1–8. https://doi.org/10.1016/j.cytogfr.2018.12.002. Epub 2018 Dec 12.
PMID: 30563755.
156
Klampfer, L. (2011). Cytokines, inflammation, and colon cancer. Current Cancer Drug Targets 11 (4):
451–464. https://doi.org/10.2174/156800911795538066. PMID: 21247378; PMCID: PMC3540985.
157 Moradinasab, S., Pourbagheri-Sigaroodi, A., Ghaffari, S.H. et al. (2022). Targeting macrophage-
mediated tumor cell phagocytosis: an overview of phagocytosis checkpoints blockade,
nanomedicine intervention, and engineered CAR-macrophage therapy. International
Immunopharmacology 103: 108499. https://doi.org/10.1016/j.intimp.2021.108499. Epub 2021
Dec 28. PMID: 34972068.
https://t.me/medicina_free
10 Nanodelivery of Polyphenols as Nutraceuticals in Anticancer Interventions
220
158 Stevens, J.F., Revel, J.S., and Maier, C.S. (2018). Mitochondria-centric review of polyphenol
bioactivity in cancer models. Antioxid Redox Signal 29 (16): 1589–1611. https://doi.org/10.1089/
ars.2017.7404. Epub 2017 Dec 11. PMID: 29084444; PMCID: PMC6207154.
159
Boedtkjer, E. and Pedersen, S.F. (2020). The acidic tumor microenvironment as a driver of cancer.
Annual Review of Physiology 82: 103–126. https://doi.org/10.1146/annurev-
physiol-021119-034627. Epub 2019 Nov 15. PMID: 31730395.
160
Chen, W., Ju, X., Aluko, R.E. et al. (2020). Rice bran protein-based nanoemulsion carrier for
improving stability and bioavailability of quercetin. Food Hydrocoll 108: 106042. https://doi.
org/10.1016/j.foodhyd.2020.106042.
161 del Mar Blanquer-Rossello, M., Herna´ndez-Lo´pez, R., Roca, P. et al. (2017). Resveratrol induces
mitochondrial respiration and apoptosis in SW620 colon cancer cells. BiochimBiophys Acta 1861:
431–440.
162
Fantin, V.R., St-Pierre, J., and Leder, P. (2006). Attenuation of LDH-A expression uncovers a link
between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 (6):
425–434. https://doi.org/10.1016/j.ccr.2006.04.023. Erratum in: Cancer Cell. 2006 Aug;10(2):172.
PMID: 16766262.
163 Mo, H., Chen, Y., Huang, L. et al. (2013). Neuroprotective effect of tea polyphenols on
oxyhemoglobin induced subarachnoid hemorrhage in mice. Oxidative Medicine and Cellular
Longevity 2013: 743938. https://doi.org/10.1155/2013/743938. Epub 2013 Jun 3. PMID: 23840920;
PMCID: PMC3686094.
164 Rupiani, S., Guidotti, L., Manerba, M. et al. (2016). Synthesis of natural urolithin M6, a galloflavin
mimetic, as a potential inhibitor of lactate dehydrogenase A. Organic & Biomolecular Chemistry
14: 10981–10987.
165
Arumugam, M., Raes, J., Pelletier, E. et al. (2011). Enterotypes of the human gut microbiome.
Nature 473 (7346): 174–180. https://doi.org/10.1038/nature09944. Epub 2011 Apr 20. Erratum in:
Nature. 474(7353):666. Erratum in: Nature. 2014 Feb 27;506(7489):516. PMID: 21508958; PMCID:
PMC3728647.
166 Wang, K., Sun, G., Conlon, M.A. et al. (2021). Editorial: dietary polyphenols for improving gut
health: volume 1. Frontiers in Nutrition 8: 760917. https://doi.org/10.3389/fnut.2021.760917.
PMID: 34671635; PMCID: PMC8520993.
167
Zhao, Y. and Jiang, Q. (2021). Roles of the polyphenol-gut microbiota interaction in
alleviating colitis and preventing colitis-associated colorectal cancer. Advances in Nutrition
12 (2): 546–565. https://doi.org/10.1093/advances/nmaa104. PMID: 32905583; PMCID:
PMC8009754.
168 Junaid, M., Linn, A.K., Javadi, M.B. et al. (2016). Vacuolating cytotoxin A (VacA) - A multi-
talented pore-forming toxin from Helicobacter pylori. Toxicon 118: 27–35. https://doi.
org/10.1016/j.toxicon.2016.04.037. Epub 2016 Apr 20. PMID: 27105670.
169 Gobert, A.P. and Wilson, K.T. (2016). The immune battle against helicobacter pylori infection: no
offense. Trends in Microbiology 24 (5): 366–376. https://doi.org/10.1016/j.tim.2016.02.005. Epub.
PMID: 26916789; PMCID: PMC4841705.
170
Tombola, F., Campello, S., De Luca, L. et al. (2003). Plant polyphenols inhibit VacA, a toxin
secreted by the gastric pathogen Helicobacter pylori. FEBS Letters 543 (1–3): 184–189. https://doi.
org/10.1016/s0014-5793(03)00443-5. PMID: 12753930.
171 Ansari, S. and Yamaoka, Y. (2020). Role of vacuolating cytotoxin A in Helicobacter pylori
infection and its impact on gastric pathogenesis. Expert Review of Anti-infective Therapy 18 (10):
987–996. https://doi.org/10.1080/14787210.2020.1782739. Epub 2020 Jun 27. PMID: 32536287.
https://t.me/medicina_free
References 221
172 Chaturvedi, M., Mishra, M., Pandey, A. et al. (2022). Oxidative products of curcumin rather than
curcumin bind to helicobacter pylori virulence factor vaca and are required to inhibit its
vacuolation activity. Molecules 27 (19): 6727. https://doi.org/10.3390/molecules27196727. PMID:
36235264; PMCID: PMC9572645.
173
Ozdal, T., Sela, D.A., Xiao, J. et al. (2016). The reciprocal interactions between polyphenols and
gut microbiota and effects on bioaccessibility. Nutrients 8 (2): 78. https://doi.org/10.3390/
nu8020078. PMID: 26861391; PMCID: PMC4772042.
174
Makarewicz, M., Drożdż, I., Tarko, T., and Duda-Chodak, A. (2021). The interactions between
polyphenols and microorganisms, especially gut microbiota. Antioxidants (Basel) 10 (2): 188.
https://doi.org/10.3390/antiox10020188. PMID: 33525629; PMCID: PMC7911950.
175
González-Sarrías, A., García-Villalba, R., Romo-Vaquero, M. et al. (2017). Clustering according to
urolithin metabotype explains the interindividual variability in the improvement of
cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: a
randomized clinical trial. Molecular Nutrition and Food Research 61 (5): https:doi.org/10.1002/
mnfr.201600830. https:doi.org/10.1002/mnfr.201600830.
176 Corrȇa, T.A.F., Rogero, M.M., Hassimotto, N.M.A., and Lajolo, F.M. (2019). The two-way
polyphenols-microbiota interaction and their effects on obesity and related metabolic diseases.
Frontiers in Nutrition 6: 188. https://doi.org/10.3389/fnut.2019.00118.
177
Jo, M.J., Bae, S.J., Son, B.W. et al. (2013). 3,4-dihydroxyphenyl acetic acid and (+)-epoxydon
isolated from marine algae-derived microorganisms induce down regulation of epidermal growth
factor activated mitogenic signaling cascade in Hela cells. Cancer Cell International 13 (1): 49.
https://doi.org/10.1186/1475-2867-13-49. PMID: 23706036; PMCID: PMC3673896.
178 Squillaro, T., Cimini, A., Peluso, G. et al. (2018). Nano-delivery systems for encapsulation of
dietary polyphenols: an experimental approach for neurodegenerative diseases and brain tumors.
Biochemical Pharmacology 154: 303–317. https://doi.org/10.1016/j.bcp.2018.05.016.
179
Zhang, Z., Li, X., Sang, S. et al. (2022). Polyphenols as plant-based nutraceuticals: health effects,
encapsulation, nano-delivery, and application. Foods 11 (15): 2189. https://doi.org/10.3390/
foods11152189.
180
Conte, R. (2016). Polyphenols nanoencapsulation for therapeutic applications. Journal of
Biological Researchand Therapy 5 (2): https://doi.org/10.4172/2167-7956.1000139.
181
Teja, P.K., Mithiya, J., Kate, A.S. et al. (2022). Herbal nanomedicines: recent advancements,
challenges, opportunities and regulatory overview. Phytomedicine 96: 153890. https://doi.
org/10.1016/j.phymed.2021.153890.
182 Hoshyar, N., Gray, S., Han, H., and Bao, G. (2016). The effect of nanoparticle size on in vivo
pharmacokinetics and cellular interaction. Nanomedicine 11 (6): 673–692. https://doi.
org/10.2217/nnm.16.5.
183
Rizvi, S.A.A. and Saleh, A.M. (2018). Applications of nanoparticle systems in drug delivery technology.
The Saudi Pharmaceutical Journal 26 (1): 64–70. https://doi.org/10.1016/j.jsps.2017.10.012.
184 de Jong, W.H. (2008). Drug delivery and nanoparticles: applications and hazards. International
Journal of Nanomedicine 133. https://doi.org/10.2147/IJN.S596.
185 Khan, I., Bahuguna, A., Kumar, P. et al. (2018). In vitro and in vivo antitumor potential of
carvacrol nanoemulsion against human lung adenocarcinoma A549 cells via mitochondrial
mediated apoptosis. Scientific Reports 8 (1): 144. https://doi.org/10.1038/s41598-017-18644-9.
186 Silva, P., Bonifácio, B., Ramos, M. et al. (2013). Nanotechnology-based drug delivery systems and
herbal medicines: a review. International Journal of Nanomedicine 1. https://doi.org/10.2147/IJN.
S52634.
https://t.me/medicina_free
10 Nanodelivery of Polyphenols as Nutraceuticals in Anticancer Interventions
222
187 Ahmed, H.M., Nabavi, S., and Behzad, S. (2021). Herbal drugs and natural products in the light of
nanotechnology and nanomedicine for developing drug formulations. Mini-Reviews in Medicinal
Chemistry 21 (3): 302–313. https://doi.org/10.2174/1389557520666200916143240.
188
Zhang, Z., Qiu, C., Li, X. et al. (2021). Advances in research on interactions between polyphenols
and biology-based nano-delivery systems and their applications in improving the bioavailability
of polyphenols. Trends in Food Science and Technology 116: 492–500. https://doi.org/10.1016/j.
tifs.2021.08.009.
189
Annaji, M., Poudel, I., Boddu, S.H.S. et al. (2021). Resveratrol‐loaded nanomedicines for cancer
applications. Cancer Reports 4 (3). https://doi.org/10.1002/cnr2.1353.
190
Emami, S., Azadmard-Damirchi, S., Peighambardoust, S.H. et al. (2016). Liposomes as carrier
vehicles for functional compounds in food sector. Journal of Experimental Nanoscience 11 (9):
737–759. https://doi.org/10.1080/17458080.2016.1148273.
191
Bhushan, B. (2016). Encyclopedia of Nanotechnology, 2e. Springer.
192 Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S. et al. (2013). Liposome: classification,
preparation, and applications. NRL 8 (1): 102. https://doi.org/10.1186/1556-276X-8-102.
193
Huang, Z., Li, X., Zhang, T. et al. (2014). Progress involving new techniques for liposome
preparation. AJPS 9 (4): 176–182. https://doi.org/10.1016/j.ajps.2014.06.001.
194
Patil, Y.P. and Jadhav, S. (2014). Novel methods for liposome preparation. Chemistry and Physics
of Lipids 177: 8–18. https://doi.org/10.1016/j.chemphyslip.2013.10.011.
195
Maja, L., Željko, K., and Mateja, P. (2020). Sustainable technologies for liposome preparation.
Journal of Supercritical Fluids 165: 104984. https://doi.org/10.1016/j.supflu.2020.104984.
196
Jourghanian, P., Ghaffari, S., Ardjmand, M. et al. (2016). Sustained release curcumin loaded solid
lipid nanoparticles. APB 6 (1): 17–21. https://doi.org/10.15171/apb.2016.04.
197
Wang, S., Chen, T., Chen, R. et al. (2012). Emodin loaded solid lipid nanoparticles: preparation,
characterization and antitumor activity studies. International Journal of Pharmaceutics 430 (1–2):
238–246. https://doi.org/10.1016/j.ijpharm.2012.03.027.
198 Yadav, A., Sunkaria, A., Singhal, N., and Sandhir, R. (2018). Resveratrol-loaded solid lipid
nanoparticles attenuate mitochondrial oxidative stress in vascular dementia by activating Nrf2/HO-1
pathway. Neurochemistry International 112: 239–254. https://doi.org/10.1016/j.neuint.2017.08.001.
199 Atef, E. and Belmonte, A.A. (2008). Formulation and in vitro and in vivo characterization of a
phenytoin self-emulsifying drug delivery system (SEDDS). European Journal of Pharmaceutical
Sciences 35 (4): 257–263. https://doi.org/10.1016/j.ejps.2008.07.004.
200 Yahaya, Z.S., Oyi, A.R., Allagh, T.S. et al. (2020). Solid self-emulsifying drug delivery system for
artemether with improved physicochemical properties: design and characterization. West African
Pharmacist 31 (1): 164–175.
201 Feeney, O.M., Crum, M.F., McEvoy, C.L. et al. (2016). 50 years of oral lipid-based formulations:
provenance, progress and future perspectives. Advanced Drug Delivery Reviews 101: 167–194.
https://doi.org/10.1016/j.addr.2016.04.007.
202
Zhao, Y., Wang, C., Chow, A.H.L. et al. (2010). Self-nanoemulsifying drug delivery system
(SNEDDS) for oral delivery of Zedoary essential oil: formulation and bioavailability studies.
International Journal of Pharmaceutics 383 (1–2): 170–177. https://doi.org/10.1016/j.
ijpharm.2009.08.035.
203 Shukla, M., Jaiswal, S., Sharma, A. et al. (2017). A combination of complexation and self-
nanoemulsifying drug delivery system for enhancing oral bioavailability and anticancer efficacy
of curcumin. Drug Development and Industrial Pharmacy 43 (5): 847–861. https://doi.org/10.1080
/03639045.2016.1239732.
https://t.me/medicina_free
References 223
204 Li, G., Zhang, Z., Liu, H., and Hu, L. (2021). Nanoemulsion-based delivery approaches for
nutraceuticals: fabrication, application, characterization, biological fate, potential toxicity and
future trends. Food and Function 12: 1933–1953. https://doi.org/10.1039/d0fo02686g. rsc.
li/
food-function.
205
Tripathi, C.B., Beg, S., Kaur, R. et al. (2016). Systematic development of optimized SNEDDS of
artemether with improved biopharmaceutical and antimalarial potential. Drug Delivery 23 (9):
3209–3223. https://doi.org/10.3109/10717544.2016.1162876.
206
Barani, M., Sangiovanni, E., Angarano, M. et al. (2021). Phytosomes as innovative delivery
systems for phytochemicals: a comprehensive review of literature. International Journal of
Nanomedicine 16: 6983–7022. https://doi.org/10.2147/IJN.S318416.
207
Lu, M., Qiu, Q., Luo, X. et al. (2019). Phyto-phospholipid complexes (phytosomes): a novel
strategy to improve the bioavailability of active constituents. Asian Journal of Pharmaceutical
Sciences 14 (3): 265–274. https://doi.org/10.1016/j.ajps.2018.05.011.
208
Mallakpour, S. and Behranvand, V. (2016). Polymeric nanoparticles: recent development in
synthesis and application. EXPRESS Polymer Letters 10 (11): 895–913. https://doi.org/10.3144/
expresspolymlett.2016.84.
209
Zielińska, A., Carreiró, F., Oliveira, A.M. et al. (2020). Polymeric nanoparticles: production,
characterization, toxicology, and ecotoxicology. Molecules 25 (16): 3731. https://doi.org/10.3390/
molecules25163731.
210
Velavan, P., Karuppusamy, C., and Venkatesan, P. (2016). Nanoparticles as drug delivery systems.
Journal of Pharmaceutical Sciences 7 (12): 1118–1122.
211
Xie, X., Tao, Q., Zou, Y. et al. (2011). PLGA nanoparticles improve the oral bioavailability of
curcumin in rats: characterizations and mechanisms. Journal of Agricultural and Food Chemistry
59 (17): 9280–9289. https://doi.org/10.1021/jf202135j.
212 Manikkam, R. and Pitchai, D. (2014). Catechin loaded chitosan nanoparticles as a novel drug
delivery system for cancer – synthesis and in vitro and in vivo characterization. World Journal of
Pharmacy and Pharmaceutical Sciences 3: 1553–1577.
213
Singh, N.A., Mandal, A.K.A., and Khan, Z.A. (2017). Fabrication of PLA-PEG nanoparticles as
delivery systems for improved stability and controlled release of catechin. Journal of
Nanomaterials. https://doi.org/10.1155/2017/6907149.
214
Xu, W., Ling, P., and Zhang, T. (2013). Polymeric micelles, a promising drug delivery system to
enhance bioavailability of poorly water-soluble drugs. Journal of Drug Delivery 1–15. https://doi.
org/10.1155/2013/340315.
215 Naseri, S., Darroudi, M., Aryan, E. et al. (2017). The antiviral effects of curcumin nanomicelles on
the attachment and entry of Hepatitis C virus. Iranian Journal of Virology 11: 29–35.
216 El-Far, M., Salah, N., Essam, A. et al. (2018). Silymarin nanoformulation as potential anticancer
agent in experimental Ehrlich ascites carcinoma-bearing animals. Nanomedicine 13 (15):
1865–1858. https://doi.org/10.2217/nnm-2017-0394.
217
Samrot, A.V., Sean, T.C., Kudaiyappan, T. et al. (2020). Production, characterization and
application of nanocarriers made of polysaccharides, proteins, bio-polyesters and other
biopolymers: a review. International Journal of Biological Macromolecules 165: 3088–3105.
https://doi.org/10.1016/j.ijbiomac.2020.10.104.
218 Lozano-Pérez, A.A., Rivero, H.C., Pérez Hernández, M.D.C. et al. (2017). Silk fibroin
nanoparticles: efficient vehicles for the natural antioxidant quercetin. International Journal of
Pharmaceutics 518 (1–2): 11–19. https://doi.org/10.1016/j.ijpharm.2016.12.046.
https://t.me/medicina_free
10 Nanodelivery of Polyphenols as Nutraceuticals in Anticancer Interventions
224
219 Solghi, S., Emam‐Djomeh, Z., Fathi, M., and Farahani, F. (2020). The encapsulation of curcumin
by whey protein: assessment of the stability and bioactivity. Journal of Food Process Engineering
43 (6): e13403. https://doi.org/10.1111/jfpe.13403.
220
Xiong, J., Chan, Y.H., Rathinasabapathy, T. et al. (2020). Enhanced stability of berry pomace
polyphenols delivered in protein-polyphenol aggregate particles to an in vitro gastrointestinal
digestion model. Food Chemistry 331: 127279. https://doi.org/10.1016/j.foodchem.2020.127279.
221
Lei, C., Liu, X.-R., Chen, Q.-B. et al. (2021). Hyaluronic acid and albumin-based nanoparticles for
drug delivery. The Journal of Controlled Release 331: 416–433. https://doi.org/10.1016/j.
jconrel.2021.01.033.
222 Abbasi, E., Aval, S.F., Akbarzadeh, A. et al. (2014). Dendrimers: synthesis, applications, and
properties. Nanoscale Research Letters 9 (1): 247. https://doi.org/10.1186/1556-276X-9-247.
223
Yetisgin, A.A., Cetinel, S., Zuvin, M. et al. (2020). Therapeutic nanoparticles and their targeted
delivery applications. Molecules 25 (9): 2193. https://doi.org/10.3390/molecules25092193.
224
Svenson, S. and Tomalia, D. (2005). Dendrimers in biomedical applications—reflections on the
field. Advanced Drug Delivery Reviews 57 (15): 2106–2129. https://doi.org/10.1016/j.
addr.2005.09.018.
225
Mollazade, M., Nejati-Koshki, K., Akbarzadeh, A. et al. (2013). PAMAM dendrimers augment
inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase.
APJCP 14 (11): 6925–6928. https://doi.org/10.7314/APJCP.2013.14.11.6925.
226
Madaan, K., Kumar, S., Poonia, N. et al. (2014). Dendrimers in drug delivery and targeting:
drug-dendrimer interactions and toxicity issues. Journal of Pharmacy and Bioallied Sciences 6 (3):
139. https://doi.org/10.4103/0975-7406.130965.
https://t.me/medicina_free
225
Polyphenols: Food, Nutraceutical, and Nanotherapeutic Applications, First Edition. Edited by Mithun Rudrapal.
© 2024 John Wiley & Sons, Inc. Published 2024 by John Wiley & Sons, Inc.
11
Nanodelivery of Polyphenols as Nutraceuticals for CNS Disorders
Puneet K. Samaiya, Rakesh Sagar, Sharad P. Pandey, Gourav Jain, and
Abhishek K. Sah*
Department of Pharmacy, Shri Govindram Seksariya Institute of Technology & Science (SGSITS), Indore, Madhya Pradesh, India
* Corresponding author
The prevalence of central nervous system (CNS) disorders is on the rise, presenting significant
challenges to human survival and resulting in a surge in healthcare costs. Neurological disorders
are the leading cause of global disability-adjusted life-years (DALYs), accounting for 45%–11.6%
of global DALYs and 16.5% of deaths in 2019. Serious threats to human health include major
CNS disorders such as brain tumors, neurodegenerative diseases, and cerebrovascular diseases
(Figure 11.1). The effective treatment of CNS disorders is impeded by the blood–brain barrier
(BBB), which comprises various cell types such as endothelial cells, astrocytes, microglial cells,
and pericytes.
11.1 Gliomas
A glioma is a type of tumor that arises from the supportive cells of the CNS, known as glial cells.
These tumors are the most common type of primary CNS tumors, accounting for approximately
24% of all cases [1]. There are various types of gliomas, including ependymomas, astrocytomas
(including glioblastoma [GBM]), oligodendrogliomas, mixed gliomas, as well as optic nerve and
brain stem gliomas [2]. In the recent classification of gliomas, in addition to histological findings
supported by ancillary tissue-based tests (e.g., immunohistochemical, ultrastructural), molecular
biomarkers have gained importance in providing both ancillary and defining diagnostic informa-
tion. In the recent 5th edition of the World Health Organization (WHO) classification of CNS
tumors, classification of gliomas has been based on key diagnostic genes, molecules, pathways,
and/or their combinations in gliomas [3]. The median survival time of patients suffering from glio-
mas is approximately 10 months. The United States Food and Drug Administration (US FDA)
granted accelerated approval of bevacizumab, a humanized monoclonal antibody against vascular
endothelial growth factor, for the treatment of recurrent glioblastomas [4]. However, in recent
years, oncolytic virus therapy, stem cell therapy, immunotherapy, and electric field therapy have
been available [5]. These emerging treatments are expected to improve the prospect of treating
recurrent high-grade gliomas.
https://t.me/medicina_free
11 Nanodelivery of Polyphenols as Nutraceuticals for CNS Disorders
226
11.2 Neurodegenerative Disorders
11.2.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia in adults. AD is a progressive
disorder with the pathological hallmarks of extracellular amyloid-β (Aβ) plaques and neurofibril-
lary tangles of intraneuronal hyperphosphorylated tau protein. According to The World Alzheimer
Report 2021 [6], AD-related dementia is the 7
th
leading cause of mortality globally. Currently,
approximately 55 million people have dementia worldwide, with Alzheimer’s accounting for nearly
70% of diagnoses. According to the World Health Organization, 10 million cases are reported each
year, with projections of 78 million people affected by 2030 and 139 million by 2050[7]. The progres-
sion from being an average person to an AD patient typically occurs in the following manner: first,
there is no cognitive impairment (NCI), then there is mild cognitive impairment (MCI), and finally,
there is AD (dementia) [8, 9]. The earliest stages of AD are asymptomatic, which are no different
from normal aging. The mild cognitive impairment (MCI) stage is characterized by a slight impair-
ment of cognition (orientation, language, attention, and executive functions might be affected), usu-
ally in memory, though not demented [10]. The last stage is AD dementia, characterized by a
significant loss of memory and cognitive functions [11]. Two forms of AD have been reported: early
onset AD occurring before 65 years of age, manifesting in 5%–10% of the population, and late onset
of AD manifesting after 65 years of age [12]. The clinical trials have failed so far as it is very difficult
to detect the pathology in the early state in most high-risk individuals [13]. This can also be why
therapeutic interventions can only offer symptomatic relief to AD patients and do not prevent AD
from originating in the individual or curing it. Researchers have proposed various hypotheses for
Cerebrovascular disease
Gliomas
Alzheimer's
Parkinson's
Amyotrophic
lateral sclerosis
Huntington's disease
Central nervous
system disorders
Figure 11.1 Types of central nervous system (CNS) disorders.
https://t.me/medicina_free
11.2 Neurodegenerative Disorders 227
the progression and development of AD; however, the cause and actual mechanism of AD remains
known. A fast response to the first symptoms of AD is crucial in diagnosing the early stages of the
disease so that treatment can be initiated and the quality of life extended [14]. In the conventional
pharmacological treatment of AD, cholinesterase inhibitors (ChEIs), such as donepezil, tacrine,
berberine, and galantamine, are employed for symptomatic treatment of AD. Many other therapeu-
tic strategies have been explored for several decades in clinical trials; however, the currently avail-
able treatments are primarily treatments of symptoms rather than actual curative therapies [15].
Because of this, attention has turned towards prevention or reducing AD risk.
11.2.2 Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, impacting
1%–2% of the population aged 65 and older [16]. The characteristic features of PD include the spe-
cific degeneration of dopaminergic neurons in the substantia nigra, as well as the accumulation of
misfolded and aggregated alpha-synuclein in the brainstem, resulting in challenges with the motor
function. Some other molecular pathogenic mechanisms include mitochondrial dysfunction,
impairment of protein clearance (associated with deficient ubiquitin-proteasome and autophagy-
lysosomal systems), neuroinflammation, and oxidative stress [17]. Enhancing the level of dopa-
mine in the brain is the most common treatment strategy to improve the symptoms in PD patients.
However, this treatment does not alter the progression of the disease or restore the affected dopa-
minergic neurons. L-dopa, amantadine, metatyrosine, melatonin, thyrotrophin-releasing hor-
mone, lithium, baclofen, electroconvulsive shock therapy, vitamin E, and marijuana are some
regimes to provide symptomatic relief in PD [18]. One of the biggest challenges in the development
of potential neuroprotective therapies has been the lack of reliable and sensitive biomarkers of
disease progression. Immunotherapies, such as the use of vaccination or monoclonal antibodies
directed against aggregated, toxic α-synuclein as well as anti-aggregation or protein clearance
strategies, are currently being investigated in clinical trials [17, 19].
11.2.3 Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a degenerative neurological condition that gradually causes
motor neurons in the CNS to deteriorate, ultimately resulting in paralysis [20]. It has been reported
that ALS affects approximately 16,000 individuals, with a prognosis for survival of 2–5 years [21].
There are two types of ALS diseases differentiated by genetics: familial and sporadic (idiopathic)
[22]. Diagnosis is determined by excluding other conditions and utilizing clinical examinations,
laboratory tests, and nerve conduction/electromyography studies [20]. The pathogenesis of ALS
comprises of failure of the upper motor neurons leading to abrupt reflexes and reduced coordina-
tion of the limbs with stiffness of the muscles. Alternatively, the failure of lower motor neurons
causes progressive atrophies when the synapses connecting the muscles are lost, which tends to
begin in the limbs and progresses to the eye and sphincter muscle neurons in the late stages.
Overall, the patients has difficulty with speaking, chewing, or swallowing [23].
11.2.4 Huntington’s Disease
Huntington’s disease (HD) is an inherited neurodegenerative disease characterized by neuropsychi-
atric symptoms, a movement disorder (most commonly choreiform) and progressive cognitive
impairment [24]. HD is triggered by mutation of the Huntingtin gene, leading to anomalies in the
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана